Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Lymphocytic, Chronic, B-Cell 7Myelodysplastic Syndromes 6Hematologic Neoplasms 6Multiple Myeloma 5Leukemia 5Burkitt Lymphoma 5Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Lymphoma 4Recurrence 3Melanoma 3Lymphoma, Mantle-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Biphenotypic, Acute 3Breast Neoplasms 3Stomach Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, Prolymphocytic 2Hematologic Diseases 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2

Interventions

fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Mesothelin-positive Advanced Refractory Solid Tumors × fludarabine × Clear all
NCT05531708 2023-03-01

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Shanghai Pudong Hospital

Phase 1 Withdrawn
Other solid neoplasm

Mesothelin-positive Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡